

Date: 12<sup>th</sup> February, 2019

To,  
BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400001.  
Scrip Code: 511523

**Sub.: Unaudited Financial Results for the quarter ended December 31, 2018**

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

1. Statement showing the Unaudited Financial Results for the quarter ended December 31, 2018.
2. Limited Review Report on the Unaudited Financial Results for the quarter ended December 31, 2018.

Thanking You.

Yours faithfully,  
For Veerhealth Care Limited



Bhavin S. Shah  
Managing Director  
DIN: 03129574



Encl: As above

VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 Fax. No. 022-22072644 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

Statement of Unaudited Financial Results for the Quarter ended December 31, 2018

(Rs. in lakhs)

Sr. No.	Particulars	Standalone					
		Quarter ended 31-12-2018	Quarter ended 30-09-2018	Quarter ended 31-12-2017	Nine months ended 31-12-2018	Nine months ended 31-12-2017	Year ended 31-03-2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	167.57	91.17	151.18	367.95	351.20	516.93
II	Other Income	5.34	5.60	22.06	16.59	59.73	72.02
III	<b>Total Revenue (I + II)</b>	<b>172.91</b>	<b>96.77</b>	<b>173.24</b>	<b>384.54</b>	<b>410.93</b>	<b>588.95</b>
IV	<b>Expenses:</b>						
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	156.29	34.15	105.61	231.66	222.67	308.38
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-69.59	-1.10	-15.54	-53.78	-22.03	59.42
	(d) Employee benefits expense	12.60	8.83	17.12	34.36	42.28	57.16
	(e) Finance Costs	0.75	1.17	1.71	3.31	5.50	7.09
	(f) Depreciation and amortisation expense	8.07	8.00	7.81	23.98	19.64	27.48
	(g) Other expenses	19.32	19.86	25.34	56.41	52.35	104.36
	<b>Total Expenses</b>	<b>127.44</b>	<b>70.91</b>	<b>142.05</b>	<b>295.94</b>	<b>320.41</b>	<b>563.88</b>
V	<b>Profit/(Loss) before exceptional items (III - IV)</b>	<b>45.47</b>	<b>25.86</b>	<b>31.19</b>	<b>88.60</b>	<b>90.52</b>	<b>25.07</b>
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit before tax (V - VI)</b>	<b>45.47</b>	<b>25.86</b>	<b>31.19</b>	<b>88.60</b>	<b>90.52</b>	<b>25.07</b>
VIII	<b>Tax expense:</b>						
	1) Current Tax	7.40	4.75	0.00	15.70	0.00	5.19
	2) Deferred Tax	0.00	0.00	0.00	0.00	0.00	6.16
IX	<b>Profit/(Loss) for the period (VII - VIII)</b>	<b>38.07</b>	<b>21.11</b>	<b>31.19</b>	<b>72.90</b>	<b>90.52</b>	<b>13.71</b>
X	<b>Other Comprehensive Income</b>						
	(a) Items that will not be reclassified to Profit or Loss	0.45	0.45	0.00	1.35	0.00	1.72
	(b) Income Tax effect on above	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Other Comprehensive Income</b>	<b>0.45</b>	<b>0.45</b>	<b>0.00</b>	<b>1.35</b>	<b>0.00</b>	<b>1.72</b>
XI	<b>Total Comprehensive Income for the period (IX + X)</b>	<b>38.52</b>	<b>21.56</b>	<b>31.19</b>	<b>74.25</b>	<b>90.52</b>	<b>15.43</b>
XII	Paid-up equity share capital of Rs. 10 each	693.42	693.42	693.42	693.42	693.42	693.42
XIII	Other Equity						616.79
XIV	Net Worth						1310.21
XV	<b>Earnings Per Share (of Rs. 10 each):</b>						
	(a) Basic (in Rs.)	0.55	0.30	0.45	1.05	1.31	0.20
	(b) Diluted (in Rs.)	0.55	0.30	0.45	1.05	1.31	0.20

*K. Srinivas*



VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 Fax. No. 022-22072644 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

NOTES:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 12th February, 2019. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the Statutory Auditors. The limited review report does not contain any observation which would have an impact on the above results.
- 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder and guidelines issued by the Securities and Exchange Board of India ('SEBI').
- 3 The Company has one segment of activity namely "Ayurved Pharma Products".
- 4 Figures of the previous periods have been regrouped, wherever necessary.
- 5 The financial results of the Company are available at www.bseindia.com, at www.msei.in and at www.veerhealthcare.net.

Place: Mumbai  
Date: 12th February, 2019



By order of the Board  
For Veerhealth Care Limited

A handwritten signature in black ink, appearing to read 'Bhavin S. Shah'.

Bhavin S. Shah  
Managing Director  
DIN: 03129574



**Limited Review Report**

**To the Board of Directors of Veerhealth Care Limited**

We have reviewed the accompanying statement of Unaudited Financial Results ("the Statement") of M/s. Veerhealth Care Limited ("the Company") for the quarter and nine months ended December 31, 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 (the "Listing Regulations").

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an Audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the applicable accounting standards, i.e., the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M. H. Dalal & Associates  
Chartered Accountants  
FRN: 112449W

Devang M. Dalal  
Partner  
M. No. 109049



Place: Mumbai  
Date: 12<sup>th</sup> February, 2019